Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGeynisman, Daniel M.
dc.contributor.authorBurotto, Mauricio
dc.contributor.authorPorta, Camillo
dc.contributor.authorSuárez Rodríguez, Cristina
dc.contributor.authorBourlon, Maria T.
dc.contributor.authorHuo, Stephen
dc.date.accessioned2022-09-09T13:40:26Z
dc.date.available2022-09-09T13:40:26Z
dc.date.issued2022-07
dc.identifier.citationGeynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, et al. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clin Drug Investig. 2022 Jul;42:611–622.
dc.identifier.issn1179-1918
dc.identifier.urihttp://hdl.handle.net/11351/8126
dc.descriptionCarcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical Drug Investigation;42
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectFetge - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subjectMedicaments antineoplàstics - Efectes secundaris
dc.subject.meshCarcinoma, Renal Cell
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleTemporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s40261-022-01170-6
dc.subject.decscarcinoma de células renales
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1007/s40261-022-01170-6
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Geynisman DM] Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. [Burotto M] Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile. [Porta C] Interdisciplinary Department of Medicine, University of Bari ‘A.Moro’ and Division of Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy. [Suarez C] Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bourlon MT] Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. [Huo S] Worldwide Health Economics and Outcomes Research-US Market, Bristol Myers Squibb, Princeton, NJ, USA
dc.identifier.pmid35696045
dc.identifier.wos000810311300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple